- Home
- CHI vs CSTL Comparison
CHI vs CSTL Comparison
Compare CHI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | CSTL |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.3M | 940.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CHI | CSTL |
|---|---|---|
| Price | $11.69 | $33.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 186.2K | ★ 403.7K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $343,530,000.00 |
| Revenue This Year | N/A | $2.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $9.70 | $14.59 |
| 52 Week High | $11.61 | $44.28 |
Technical Indicators
Market Signals| Indicator | CHI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 30.87 |
| Support Level | $11.00 | $31.38 |
| Resistance Level | $11.60 | $33.10 |
| Average True Range (ATR) | 0.18 | 1.87 |
| MACD | 0.01 | -0.75 |
| Stochastic Oscillator | 65.00 | 11.64 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.